BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients

BDX's Revello stent shows strong nine-month AGILITY trial results, with high vessel patency and low failure rates, boosting its peripheral vascular prospects.

Zacks Investment Research • Oct 15, 2026

3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades

Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics.

24/7 Wall Street • Oct 15, 2026

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 9, 2026

BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026

FRANKLIN LAKES, N.J., Oct. 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.

PRNewsWire • Oct 8, 2026

BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide

Physicians, policymakers, and global health experts urge broader access to monitoring technologies that can help identify life-threatening complications earlier, helping more mothers survive childbirth and giving babies a healthier start in life. FRANKLIN LAKES, N.J.

PRNewsWire • Oct 8, 2026

BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results

Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease. FRANKLIN LAKES, N.J.

PRNewsWire • Oct 7, 2026

BDX Expands U.S. Manufacturing With $19B Healthcare Investment

BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.

Zacks Investment Research • Oct 7, 2026

Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing

Becton, Dickinson and Company (NYSE:BDX), a global medical technology firm and the largest domestic producer of critical medical consumables, on Tuesday announced a monumental partnership with the U.S. government.

Benzinga • Oct 6, 2026

BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience

Agreement supports significant investments in U.S. manufacturing, strengthens healthcare resilience and increases domestic production of essential medical consumables used in approximately 90% of U.S. hospital visits    FRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), one of the world's leading medical technology companies and the nation's largest manufacturer of essential medical consumables, today announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by clinicians and patients every day.

PRNewsWire • Oct 6, 2026

BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan

Generations of Connecticut employees have helped ensure the reliable supply of the BD® Syringe, an essential medical device clinicians rely on every day in patient care around the world CANAAN, Conn., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 65 years of manufacturing in Canaan, Conn.

PRNewsWire • Oct 6, 2026